ARTICLE | Product Development
U.K., South African data backup plan for Novavax in U.S.
U.S. Phase III trial delayed as leading vaccines near FDA authorization
December 1, 2020 12:32 AM UTC
A delay in starting the U.S. Phase III trial for its COVID-19 vaccine candidate means Novavax may have to rely on data from U.K. and South African trials to seek emergency use authorization in the U.S.
As it announced the delay, Novavax Inc. (NASDAQ:NVAX) also said Monday that it has completed enrollment of a U.K. Phase III trial and of a South African Phase IIb of its COVID-19 vaccine candidate. Shares in the company rose 11% to $139.50, adding $850 million in market cap...